Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C

Table 3 Aminoacid substitutions in HCV NS3 protease region associated with resistance to DAAs^a in treatment-naïve patients

R^b	P^c	D^d	M^e	Drug	G 1b (n = 11)	G 2c (n = 11)	G 4d (n = 6)
NS3	16	C	S	ACH806	*C/R(9)	*A(100)	*T(100)
NS3	36	V	A,M,G,L	Telaprevir, Boceprevir	*V(100)	L(100)^f	L(100)^f
NS3	54	T	A,S	Telaprevir, Boceprevir	^•	^•	^•
NS3	155	R	K,T,I,MG,L,S,Q	Telaprevir, Boceprevir	^•	^•	^•
NS3	156	A	S,T,V,I	Telaprevir, Boceprevir	^•	^•	^•
NS3	168	D	Q,A,V,E,T	TMC435,R7227,MK7009, BI201335, BILN2061	^•	^•	^•
NS3	175	M	L	Telaprevir	*M(100)	L(100)^f	L(100)^f

^a direct acting antiviral agents
R^b, Region; P^c,Position aa; D^d,Dominant aa; M^e, Mutant aa; (Lopez-Labrador, 2008; Lentz, 2010; Kieffer [15], Halfon [13], Kuntzen [19])
*Percentage of sequences with substitutions
•The dominant residue is found in 100 % of analyzed sequences for each genotype
^f Substitution found is associated with resistance in genotype 1b

ISSN: 1743-422X